ABEONA THERAPEUTICS INC (ABEO) Forecast, Price Target & Analyst Ratings
NASDAQ:ABEO • US00289Y2063
4.85 USD
-0.02 (-0.41%)
At close: Mar 6, 2026
4.85 USD
0 (0%)
After Hours: 3/6/2026, 8:00:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ABEONA THERAPEUTICS INC (ABEO).
Forecast Snapshot
Consensus Price Target
$21.06
+ 334.14% Upside
Next Earnings Forecast
Release DateMar 23, 2026
PeriodQ4 / 2025
EPS Estimate-$0.34
Revenue Estimate6.36M
ChartMill Buy Consensus
86.67%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$21.06
Upside
+ 334.14%
From current price of $4.85 to mean target of $21.06, Based on 12 analyst forecasts
Low
$14.14
Median
$19.38
High
$29.40
Price Target Revisions
1 Month
0.00%
3 Months
2.12%
Price Target Summary
12 analysts have analysed ABEO and the average price target is 21.06 USD. This implies a price increase of 334.14% is expected in the next year compared to the current price of 4.85.
The average price target has been revised upward by 2.12% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
ABEO was analyzed by 12 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about ABEO.
In the previous month the buy percentage consensus was at a similar level.
ABEO was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-10-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-16 | Stifel | Maintains | Buy -> Buy |
| 2025-04-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-05 | Oppenheimer | Initiate | Outperform |
| 2025-02-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-29 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-03 | HC Wainwright & Co. | Initiate | Buy |
| 2024-05-30 | Stifel | Initiate | Buy |
| 2024-05-16 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-04-23 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-24 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-07-13 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-24 | Alliance Global Partners | Reiterate | Buy |
| 2022-11-14 | SVB Leerink | Maintains | Market Perform |
| 2022-11-08 | Cantor Fitzgerald | Maintains | Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 23, 2026
PeriodQ4 / 2025
EPS Estimate-$0.34
Revenue Estimate6.36M
Revenue Q2QN/A
EPS Q2Q-140.43%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
-4.21%
EPS (3 Months)
-4.21%
Next Earnings Summary
ABEO is expected to report earnings on 3/23/2026. The consensus EPS estimate for the next earnings is -0.34 USD and the consensus revenue estimate is 6.36M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3M -70.00% | 1.41M -53.00% | 3.5M 148.23% | 102K -100.00% | 6.766M | 114.33M 1,589.77% | 208.13M 82.04% | 310.78M 49.32% | 360.83M 16.10% | 425.77M 18.00% | 492.19M 15.60% | 512.87M 4.20% | 527.75M 2.90% | |
| EBITDA YoY % growth | -54.12M -23.25% | -42.17M 22.08% | -45.912M -8.87% | N/A -35.49% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -57.37M -18.29% | -45.26M 21.11% | -48.2M -6.50% | -65.255M -33.22% | -78.956M -22.96% | -16.578M 79.00% | 62.353M 476.12% | 123.26M 97.68% | 147.43M 19.61% | 196.1M 33.01% | 247.56M 26.24% | 260.98M 5.42% | 261.63M 0.25% | |
| Operating Margin | -1,912.33% | -3,209.93% | -1,377.14% | -63,975.60% | -1,166.96% | -14.50% | 29.96% | 39.66% | 40.86% | 46.06% | 50.30% | 50.89% | 49.57% | |
| EPS YoY % growth | -15.75 -14.55% | -5.53 64.89% | -2.71 50.99% | -1.79 35.79% | 1.26 172.22% | -0.05 -104.29% | 1.03 2,007.55% | 2.79 171.74% | 2.59 -7.30% | 2.75 6.30% | 3.59 30.37% | 3.70 3.12% | 3.99 7.71% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.34 -140.43% | -0.14 42.62% | -0.09 83.64% | 0.00 97.45% | 0.06 118.94% | 0.08 159.26% | 0.19 323.53% | 0.28 10,900.00% | 0.35 444.00% |
| Revenue Q2Q % growth | 6.36M | 19.041M | 23.004M 5,651.00% | 29.838M | 35.731M 461.81% | 33.629M 76.61% | 44.839M 94.92% | 54.805M 83.68% | 64.77M 81.27% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -20.425M -22.51% | -4.924M 75.04% | -3.83M 83.20% | -2.115M 91.19% | -1.381M 93.24% | 6.657M 235.19% | 15.675M 509.26% | 23.635M 1,217.24% | 31.086M 2,351.68% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
37.35%
EPS Next 5 Year
28.39%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
1,168.37%
Revenue Next 5 Year
412.56%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ABEONA THERAPEUTICS INC / ABEO Forecast FAQ
Can you provide the average price target for ABEONA THERAPEUTICS INC stock?
12 analysts have analysed ABEO and the average price target is 21.06 USD. This implies a price increase of 334.14% is expected in the next year compared to the current price of 4.85.
Can you provide the upcoming earnings date for ABEONA THERAPEUTICS INC?
ABEONA THERAPEUTICS INC (ABEO) will report earnings on 2026-03-23, after the market close.
What are the consensus estimates for ABEONA THERAPEUTICS INC (ABEO) next earnings?
The consensus EPS estimate for the next earnings of ABEONA THERAPEUTICS INC (ABEO) is -0.34 USD and the consensus revenue estimate is 6.36M USD.
How many analysts have analysed ABEONA THERAPEUTICS INC (ABEO)?
The number of analysts covering ABEONA THERAPEUTICS INC (ABEO) is 12.